Salani, Jawlisa B.
HRN: 25-19-87 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/15/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/15/2024
06/22/2024
IV
110mg
Q24H
PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes